Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Aide

Showing results (1-10 of 119) with videos related to

Pageof 12
Sort By:
PET Clinics|November 19, 2019
<sup>18</sup>F-Fludeoxyglucose PET/Computed Tomography for Assessing Tumor Response to Immunotherapy and Detecting Immune-Related Side Effects: A Checklist for the PET ReaderKevin Prigent, Nicolas Aide
European Journal of Nuclear Medicine and Molecular Imaging|May 26, 2017
Therapy monitoring with PET in cancer patients: achievements, opportunities and challenges ahead for the PET communityNicolas Aide, Stefano Fanti
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 6, 2007
Would patient selection based on both calcitonin blood level and doubling time improve 18F-FDG PET sensitivity in restaging of medullary thyroid cancer?Nicolas Aide, Stéphane Bardet
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2025
Metabolic Tumor Volume and Immunotherapy in NSCLC-LetterNicolas Aide, Egesta Lopci, Laurent Dercle
European Journal of Nuclear Medicine and Molecular Imaging|February 24, 2018
Reply to: "All that glitters is not gold - new reconstruction methods using Deauville criteria for patient reporting"Charline Lasnon, Blandine Enilorac, Nicolas Aide
European Journal of Nuclear Medicine and Molecular Imaging|July 16, 2018
Reply to the Letter to the Editor from Peters et al: On the use of the liver as a reference organ for Deauville scoring in lymphoma patients and how it may be affected by liver steatosisNicolas Aide, Thibault Salomon, Charline Lasnon
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2007
Enlarging residual mass after treatment of a nonseminomatous germ cell tumor: growing teratoma syndrome or cancer recurrence?Nicolas Aide, François Comoz, Emmanuel Sevin
European Journal of Nuclear Medicine and Molecular Imaging|March 26, 2021
Is it time to include [<sup>18</sup>F]FDG-PET/CT in the diagnostic work-up for lymph node staging in cN0 vulvar cancer patients?Nicolas Aide, Stephanie Markovina, Annamaria Ferrero
Diagnostics (Basel, Switzerland)|October 27, 2022
Prediction of the Presence of Targetable Molecular Alteration(s) with Clinico-Metabolic <sup>18</sup> F-FDG PET Radiomics in Non-Asian Lung Adenocarcinoma PatientsNicolas Aide, Kathleen Weyts, Charline Lasnon
European Journal of Nuclear Medicine and Molecular Imaging|February 19, 2018
Combining baseline TMTV and gene profiling for a better risk stratification in diffuse large B cell lymphomaNicolas Aide, Charline Lasnon, Gandhi Damaj
Pageof 12

Showing results (1-10 of 119) with videos related to

Sort By:
Pageof 12
PET Clinics|November 19, 2019
<sup>18</sup>F-Fludeoxyglucose PET/Computed Tomography for Assessing Tumor Response to Immunotherapy and Detecting Immune-Related Side Effects: A Checklist for the PET ReaderKevin Prigent, Nicolas Aide
European Journal of Nuclear Medicine and Molecular Imaging|May 26, 2017
Therapy monitoring with PET in cancer patients: achievements, opportunities and challenges ahead for the PET communityNicolas Aide, Stefano Fanti
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 6, 2007
Would patient selection based on both calcitonin blood level and doubling time improve 18F-FDG PET sensitivity in restaging of medullary thyroid cancer?Nicolas Aide, Stéphane Bardet
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2025
Metabolic Tumor Volume and Immunotherapy in NSCLC-LetterNicolas Aide, Egesta Lopci, Laurent Dercle
European Journal of Nuclear Medicine and Molecular Imaging|February 24, 2018
Reply to: "All that glitters is not gold - new reconstruction methods using Deauville criteria for patient reporting"Charline Lasnon, Blandine Enilorac, Nicolas Aide
European Journal of Nuclear Medicine and Molecular Imaging|July 16, 2018
Reply to the Letter to the Editor from Peters et al: On the use of the liver as a reference organ for Deauville scoring in lymphoma patients and how it may be affected by liver steatosisNicolas Aide, Thibault Salomon, Charline Lasnon
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2007
Enlarging residual mass after treatment of a nonseminomatous germ cell tumor: growing teratoma syndrome or cancer recurrence?Nicolas Aide, François Comoz, Emmanuel Sevin
European Journal of Nuclear Medicine and Molecular Imaging|March 26, 2021
Is it time to include [<sup>18</sup>F]FDG-PET/CT in the diagnostic work-up for lymph node staging in cN0 vulvar cancer patients?Nicolas Aide, Stephanie Markovina, Annamaria Ferrero
Diagnostics (Basel, Switzerland)|October 27, 2022
Prediction of the Presence of Targetable Molecular Alteration(s) with Clinico-Metabolic <sup>18</sup> F-FDG PET Radiomics in Non-Asian Lung Adenocarcinoma PatientsNicolas Aide, Kathleen Weyts, Charline Lasnon
European Journal of Nuclear Medicine and Molecular Imaging|February 19, 2018
Combining baseline TMTV and gene profiling for a better risk stratification in diffuse large B cell lymphomaNicolas Aide, Charline Lasnon, Gandhi Damaj
Pageof 12